# **Isobaric Label Quantitative Proteomics Service Overview**




#### **Service Description**

Quantitative proteomics refers to the identification and quantification analysis of proteins in two or more samples to obtain the differential expression and function information of relevant proteins. Quantitative proteomics is most often applied in research concerning the prevention, diagnosis, prognosis and efficacy monitoring of diseases, and in helping to develop therapeutic drugs.

BGI Genomics provides Isobaric Label Quantitative Proteomics services using iTRAQ (Isobaric Tags for Relative and Absolute Quantitation), IBT (Isobaric Tags for Quantitation) and TMT (Tandem Mass Tags for Quantitation) technologies developed by AB SCIEX, BGI Genomics and Thermo Scientific, respectively.

The iTRAQ reagents are the first set of multiplexed, amine-specific, stable-isotope reagents that can label the lysine residues and N terminus of all peptides in between 2 to 8 (8-plex) different biological samples/treatments enabling simultaneous identification and quantitation.



Isobaric iTRAQ reagents 8-plex workflow

Williamson B, et al., Identification and quantitation of proteins using mass spectrometry-based peptide multiplex labelling methods, (2008)

IBT protein quantitative analysis is a BGI Genomics-developed upgraded version of conventional iTRAQ protein quantitative analysis, and IBT reagents can compare 16 different samples in parallel. TMT reagents have the same principle and compare up to 18 different samples in parallel.

| TAG         | ITRAQ  |        | ТМТ     |         | IBT     |         |
|-------------|--------|--------|---------|---------|---------|---------|
| Mode        | 4-plex | 8-plex | 16-plex | 18-plex | 10-plex | 16-plex |
| Reporter 1  | 114    | 113    | 126     | 126     | 114     | 114     |
| Reporter 2  | 115    | 114    | 127N    | 127N    | 115N    | 115N    |
| Reporter 3  | 116    | 115    | 127C    | 127C    | 115C    | 115C    |
| Reporter 4  | 117    | 116    | 128N    | 128N    | 116N    | 116N    |
| Reporter 5  |        | 117    | 128C    | 128C    | 116C    | 116C    |
| Reporter 6  |        | 118    | 129N    | 129N    | 117N    | 117N    |
| Reporter 7  |        | 119    | 129C    | 129C    | 117C    | 117C    |
| Reporter 8  |        | 121    | 130N    | 130N    | 118N    | 118N    |
| Reporter 9  |        |        | 130C    | 130C    | 118C    | 118C    |
| Reporter 10 |        |        | 131N    | 131N    | 119     | 119N    |
| Reporter 11 |        |        | 131C    | 131C    |         | 119C    |
| Reporter 12 |        |        | 132N    | 132N    |         | 120N    |
| Reporter 13 |        |        | 132C    | 132C    |         | 120C    |
| Reporter 14 |        |        | 133N    | 133N    |         | 121N    |
| Reporter 15 |        |        | 133C    | 133C    |         | 121C    |
| Reporter 16 |        |        | 134N    | 134N    |         | 122     |
| Reporter 17 |        |        |         | 134C    |         |         |
| Reporter 18 |        |        |         | 135N    |         |         |

Summary of Three Isobaric Label Reagent Options

# **Research Applications**



- Disease biomarker research
- Drug efficacy evaluation
- · Special behavior mechanisms and food/medicinal value research
- Plant growth and development research
- Plant disease resistance and insect resistance research
- · Microbial stress and adversity physiology research

## **Isobaric Label Analysis Workflow**




## **BGI Genomics Service Advantages**

| High Throughput and Short Project Cycle  | High Accuracy and Repeatability   |  |  |  |
|--|---|--|--|--|
| Simultaneous proteome quantification of less than 18<br>samples. More than 18 samples can be bridged by setting<br>reference samples to realize the comparison of data, thus<br>shortening project cycle | Analysis of multiple labeled samples at the same time<br>avoids poor repeatability issues connected to testing<br>separately and with traditional gel samples |  |  |  |
|  |   |  |  |  |
| Wide Range of Biological Samples   | Cloud platform delivery   |  |  |  |


## **Bioinformatics Analysis Workflow**

#### Standard:




#### Isobaric Label Quantitative Proteomics Service Overview


## **Customized Solutions:**



# **Examples of Data QC Analysis - Stability and Repeatability**




**CV** Distribution



PCA Analysis

# **Examples of Protein Quantification Analysis**



**Quantification Statistics** 

**Cluster Analysis** 

Proteome-Transcriptome Correlation Analysis

# **General Sample Requirements**

|                  |   | AMOUNT                           |                         |
|------------------|---|----------------------------------|-------------------------|
|                  | SAMPLE TYPE   |                                  | MINIMUM                 |
| Animal           | Common animal tissues: animal internal organs<br>(heart, liver, spleen, lung, kidney), skin, muscle, brain, etc                     | ≥ 10 mg                          | ≥ 1 mg                  |
|                  | Mollusks (Toxoplasma, Schistosomiasis, Drosophila, Acarid,<br>Plutella xylostella, Laodelphax, Cestode, Cicada, Hematodinium, etc.) | ≥ 10 mg                          | ≥ 2 mg                  |
| 0.1              | Suspended cells, adherent cells   | ≥ 1×10 <sup>7</sup>              | ≥ 1×10 <sup>6</sup>     |
| Cell             | Cell culture supernatant  | ≥ 10 mL                          |                         |
| Exosome          | Exosome isolated by customer  | ≥ 50 µg, ≥ 0.5 µg/µL             |                         |
| Fluid            | Plasma, serum (remove highly-abundant protein)  | ≥ 200 µL                         | ≥ 200 µL                |
|                  | Plasma, serum (with highly-abundant protein)  | ≥ 10 µL                          | ≥ 3 µL                  |
|                  | Amniotic fluid, cerebrospinal fluid, semen, etc.<br>(remove highly-abundant protein)  | ≥1 mL                            | ≥ 500 µL                |
|                  | Amniotic fluid, cerebrospinal fluid, semen, etc.<br>(with highly-abundant protein)  | ≥ 200 µL                         | ≥ 100 µL                |
|                  | Saliva, milk  | ≥ 200 µL                         | ≥ 100 µL                |
|                  | Urine   | ≥ 30 mL                          | ≥ 15 mL                 |
|                  | Tear  | ≥ 15 µL                          | ≥ 10 µL                 |
| Plant            | Twigs of plants (leaf buds, tender leaves), algae   | ≥ 300 mg                         | ≥ 200 mg                |
|                  | Old leaves, roots, stems, bark of plants  | ≥1 g                             | ≥ 500 mg                |
|                  | Plant buds, pollen  | ≥ 100 mg                         | ≥ 50 mg                 |
|                  | Plant seeds (rice/wheat seeds, etc.),<br>fruits (apples, peaches, pears)  | ≥1g                              | ≥ 500 mg                |
| Microorganism    | Prokaryotic bacteria (E. coli, Staphylococcus aureus, etc.),<br>fungi (yeast, etc.)   | Thallus ≥ 50 mg<br>cells ≥ 5×10⁰ |                         |
| Protein solution | Complex protein solution, protein powder  | ≥ 100 µg,<br>≥ 0.5 µg/µL         | ≥ 50 µg,<br>≥ 0.5 µg/µL |

# **Turn Around Time**

Sample size: 1 batch, 4-5weeks



## **Request for Information or Quotation**

Contact a BGI Genomics representative to discuss how we can meet your specific needs or for expert advice on experiment design, from sample to bioinformatics.

info@bgi.com www.bgi.com

For Research Use Only. Not for use in diagnostic procedures (except as specifically noted).

Copyright<sup>®</sup> BGI Genomics 2023. All trademarks are the property of BGI Genomics or their respective owners. This material contains information on products targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration, or usage in the country of your origin. Please get in touch with a representative for regional availability. The company reserves the right of final interpretation.





We Sequence, You Discover